Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [2]
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 17725-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#17725-1-AP, RRID:AB_2062680
- Product name
- ATP6V1F antibody
- Antibody type
- Polyclonal
- Description
- ATP6V1F antibody (Cat. #17725-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse and has been validated for the following applications: FC, IHC, WB,ELISA.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Study on the mechanism of arsenic-induced renal injury based on SWATH proteomics technology.
Proteomic Investigation of Differential Interactomes of Glypican 1 and a Putative Disease-Modifying Variant of Ataxia.
ATP6V1F is a novel prognostic biomarker and potential immunotherapy target for hepatocellular carcinoma.
Genome-wide association studies identify miRNA-194 as a prognostic biomarker for gastrointestinal cancer by targeting ATP6V1F, PPP1R14B, BTF3L4 and SLC7A5.
Chen X, Yan X, Tang X, Wang Y, Zhang X, Cao X, Ran X, Ma G, Hu T, Qureshi A, Luo P, Shen L
Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) 2024 May;83:127390
Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) 2024 May;83:127390
Proteomic Investigation of Differential Interactomes of Glypican 1 and a Putative Disease-Modifying Variant of Ataxia.
Cengiz Winter N, Karakaya M, Mosen P, Brusius I, Anlar B, Haliloglu G, Winter D, Wirth B
Journal of proteome research 2023 Sep 1;22(9):3081-3095
Journal of proteome research 2023 Sep 1;22(9):3081-3095
ATP6V1F is a novel prognostic biomarker and potential immunotherapy target for hepatocellular carcinoma.
Hu X, Li D, Zhu H, Yu T, Xiong X, Xu X
BMC medical genomics 2023 Aug 16;16(1):188
BMC medical genomics 2023 Aug 16;16(1):188
Genome-wide association studies identify miRNA-194 as a prognostic biomarker for gastrointestinal cancer by targeting ATP6V1F, PPP1R14B, BTF3L4 and SLC7A5.
Huang P, Xia L, Guo Q, Huang C, Wang Z, Huang Y, Qin S, Leng W, Li D
Frontiers in oncology 2022;12:1025594
Frontiers in oncology 2022;12:1025594
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- MCF7 cells were subjected to SDS PAGE followed by western blot with 17725-1-AP(ATP6V1F antibody) at dilution of 1:1000
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human testis using 17725-1-AP(ATP6V1F antibody) at dilution of 1:50 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human testis using 17725-1-AP(ATP6V1F antibody) at dilution of 1:50 (under 40x lens)
- Sample type
- tissue
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The ATP6V1F antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human ATP6V1F. This antibody recognizes human, mouse antigen. The ATP6V1F antibody has been validated for the following applications: ELISA, WB, IHC, FC analysis.
